Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Abdullah M Al Alawi
 -- 1599 2023-06-29 03:18:17 |
2 references update
Fanny Huang
 Meta information modification 1599 2023-06-29 08:02:42 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Aal-Hamad, A.H.; Al-Alawi, A.M.; Kashoub, M.S.; Falhammar, H. Causes of Hypermagnesemia. Encyclopedia. Available online: https://encyclopedia.pub/entry/46194 (accessed on 18 May 2024).
Aal-Hamad AH, Al-Alawi AM, Kashoub MS, Falhammar H. Causes of Hypermagnesemia. Encyclopedia. Available at: https://encyclopedia.pub/entry/46194. Accessed May 18, 2024.
Aal-Hamad, Aya Hasan, Abdullah M. Al-Alawi, Masoud Salim Kashoub, Henrik Falhammar. "Causes of Hypermagnesemia" Encyclopedia, https://encyclopedia.pub/entry/46194 (accessed May 18, 2024).
Aal-Hamad, A.H., Al-Alawi, A.M., Kashoub, M.S., & Falhammar, H. (2023, June 29). Causes of Hypermagnesemia. In Encyclopedia. https://encyclopedia.pub/entry/46194
Aal-Hamad, Aya Hasan, et al. "Causes of Hypermagnesemia." Encyclopedia. Web. 29 June, 2023.
Causes of Hypermagnesemia
Edit
This entry is adapted from the peer-reviewed paper 10.3390/medicina59071190

Hypermagnesemia is a relatively uncommon but potentially life-threatening electrolyte disturbance characterized by elevated magnesium concentrations in the blood. Magnesium is a crucial mineral involved in various physiological functions, such as neuromuscular conduction, cardiac excitability, vasomotor tone, insulin metabolism, and muscular contraction. Prompt identification and management of hypermagnesemia are crucial to prevent complications, such as respiratory and cardiovascular negative outcomes, neuromuscular dysfunction, and coma. Preventing hypermagnesemia is crucial, particularly in high-risk populations, such as patients with impaired renal function or those receiving magnesium-containing medications or supplements. 

hypermagnesemia electrolyte disturbance

1. Introduction

Magnesium (Mg) is a vital mineral that functions as a cofactor in over 300 enzymatic reactions in the human body. It is essential for adenosine triphosphate (ATP) metabolism, DNA and RNA synthesis, and protein synthesis [1]. Moreover, it plays a critical role in regulating numerous physiological functions, including muscular contraction, blood pressure, insulin metabolism, cardiac excitability, vasomotor tone, nerve transmission, and neuromuscular conduction [1]. Hypomagnesemia is more common than hypermagnesemia and can lead to many neuromuscular, cardiac, or nervous disorders [2].
Previous studies indicate that hypomagnesemia is a prevalent electrolyte disturbance in clinical settings, particularly in patients admitted to the intensive care unit (ICU). Hypomagnesemia is associated with poor health outcomes, including prolonged length of hospital stay, increased mortality rate, and poor survival [1][3]. Unlike hypomagnesemia, hypermagnesemia is a less common condition and has not been as extensively studied in clinical practice. However, hypermagnesemia has been associated with poor health outcomes among hospitalized patients [4].

2. Epidemiology of Hypermagnesemia

In clinical settings, the evaluation of serum total Mg concentration is the primary method used to assess Mg status, with the normal reference range typically being 0.7–1.0 mmol/L (1.7–2.4 mg/dL) [1][2][5]. The normal values may differ between laboratories, and some studies have employed slightly different ranges [5]. These discrepancies in normal values may partly account for the differences in reported Mg disorders prevalence among patients with similar characteristics [1].
Unlike hypomagnesemia, few studies assessed the prevalence of hypermagnesemia in various health settings [6][7][8][9]. In a population-based prevalence study evaluating the prevalence of Mg concentrations in an urban general population (n = 1558), the overall prevalence of hypermagnesemia was 3.0% [8]. Pregnant women with eclampsia are considered to be a high-risk group due to the need for high doses of intravenous Mg to prevent eclamptic seizures [10]. However, Mg intoxication incidence was in a large systematic review involving 9556 women with Mg use due to pre-eclampsia, only 1.3–1.6% [9].
In a hospital setting, the prevalence of hypermagnesemia ranges from 5.7% to 9.3% [6][11]. The most extreme cases of elevated serum Mg concentration recorded were in a premature infant at 33 weeks gestation with a concentration of 18 mmol/L and in a 78-year-old woman who ingested water from the Dead Sea with a concentration of 13.4 mmol/L [6][7]. It has been estimated that around 10% to 15% of hospitalized patients with renal failure develop hypermagnesemia due to reduced renal excretion of Mg [12]. Hypermagnesemia was associated with poor health outcomes, including increased in-hospital mortality and 1-year mortality among hospitalized patients [4][13][14]. Moreover, hypermagnesemia strongly predicts the in-hospital mortality rate of acute myocardial infarction [15]. This may be due to Mg ions competing with the calcium ions for activation and deactivation sites located on the type II isoform ryanodine receptor channels in cardiac myocytes, damaging cardiac contraction, and relaxation [16]. Additionally, Mg can also impair the release of acetylcholine, leading to motor end-plate sensitivity depression and inducing arrhythmia, myocardial depression, and vasodilation [17].
Moreover, hypermagnesemia appears to be an indicator of disease severity among patients hospitalized with SARS-CoV-2, and hypermagnesemia was associated with prolonged hospitalization, higher rates of ICU admission, greater need for mechanical ventilation, and mortality [18].

3. Assessment of Mg Status

The commonly used method is measuring total serum magnesium concentration, although it may not provide the most reliable evaluation due to potential influences from serum protein concentrations. Recent advancements in ion-selective electrodes have enabled the measurement of ionized magnesium concentration, but standardization is needed. Red cell magnesium concentration does not correlate well with overall magnesium status while assessing magnesium content in mononuclear cells is technically challenging. Muscle magnesium content assessment through invasive procedures has shown promise in predicting cardiac magnesium levels [1][17].
A 24-h urine excretion of magnesium can reflect intestinal absorption and identify renal magnesium wasting. The magnesium tolerance test accurately determines magnesium retention after intravenous administration, but its utility is limited in patients with renal magnesium loss. Intracellular free magnesium concentration can be measured using fluorescent probes or nuclear magnetic resonance [1][19].
Magnesium balance studies, isotopic analysis, hair and tooth analysis, and enzyme activation studies have been explored, but they are less reliable than serum or red cell magnesium concentration. Overall, a combination of tests, such as measuring total serum magnesium and employing the magnesium tolerance test, currently provides the most accessible assessment of magnesium status. With advancements in technology, ionized magnesium measurement may become more widely available and reliable in the future [1][20].

4. Causes of Hypermagnesemia

4.1. Reduced Renal Excretion

Patients with either acute kidney injury or chronic kidney disease (CKD) are at increased risk of hypermagnesemia due to the importance of the renal system for Mg excretion, and 10–15% of hospitalized patients with kidney injury may develop hypermagnesemia [15]. Moreover, in rare circumstances, several endocrinological conditions might cause marked rises in serum Mg concentrations, such as hyperparathyroidism, adrenal insufficiency, and hypothyroidism, by increasing Mg renal reabsorption [21][22]. Hyperparathyroidism and calcium metabolism disturbance can result in hypermagnesemia through an increased calcium-induced Mg absorption in the tubule [23]. Familial hypocalciuric hypercalcemia (FHH) is a rare autosomal dominant condition that occurs due to a variant in the calcium-sensing receptor gene (CaSR). The CaSR presents in all the kidney segments and prominently in the basolateral side of TAL, controlling the sodium chloride and divalent cation, such as Mg and calcium, transportation both transcellularly and paracellularly by enhancing various channels such as NKCC2 and ROMK [24]. As a result of CaSR gene variations, the aforementioned channels (NKCC2 and ROMK) get over-activated and create a positive activity in the lumen, which encourages the action of the paracellin, which induces the reabsorption of the Mg and calcium transcellularly and paracellularly. In hypothyroidism, it is suggested that Mg excretion is impaired due to a drop in renal blood flow and filtration rate [25][26]. Increased sodium-potassium ATPase activity in settings of hypothyroidism has been reported, which results in a high electrochemical gradient leading to reabsorption of Mg. The latter could explain the association between hyperkaliemia and hypermagnesemia [26][27][28][29]. Finally, certain drugs that act on renal endothelial vessels and the angiotensin system might cause hypermagnesemia, such as lithium, angiotensin-converting enzyme inhibitors, and non-steroidal anti-inflammatory drugs (Table 1) [23].
Table 1. Causes of hypermagnesemia.
Category Sub-Category Causes Mechanisms
Reduced Renal Excretion Kidney Disease Acute kidney injury
Chronic kidney disease		 Reduced ability of the kidneys to excrete Mg
  Endocrinological Conditions Hyperparathyroidism
Adrenal insufficiency
Hypothyroidism		 Abnormalities in calcium metabolism or renal blood flow/filtration rate
  Certain Drugs Lithium, angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory drugs Alteration of renal endothelial vessels and angiotensin system
Increased Intake of Mg Bowel Conditions Elderly patients with bowel conditions Enhanced absorption or reduced gut motility
  Medications Anticholinergics, laxatives, and medications containing Mg Increased intake or absorption of Mg
  Other Causes Milk alkali syndrome, increased dialysate Mg, post-urethral irrigation with hemiacidrin, excessive infusion of Mg sulfate Various mechanisms
Mg Leak to Extracellular Fluid Hemolysis Tumor lysis syndrome Movement of Mg from intracellular to extracellular space
  Metabolic Acidosis Diabetic ketoacidosis Movement of Mg from intracellular to extracellular space
  Other Causes Chronic low-grade metabolic acidosis Various mechanisms

4.2. Increased Intake of Mg

Hypermagnesemia might develop in individuals despite normal renal functions, especially in elderly patients with certain bowel conditions that enhance the absorption or reduce gut motility, including inflammatory bowel diseases and constipation [30]. Similarly, anticholinergics medications or laxatives might result in high serum Mg concentrations, primarily in settings of pre-existing bowel pathology [31]. Medications containing Mg can elevate serum Mg concentrations if taken continuously, particularly when renal function is impaired. Amaguchi and colleagues reported a case of symptomatic hypermagnesemia secondary to Mg supplements in an elderly with underlying constipation [30]. In order to evaluate the risk of hypermagnesemia in patients using magnesium oxide tablets, a retrospective study was conducted involving 2176 individuals who took daily magnesium oxide for laxative purposes. The study indicated a correlation between hypermagnesemia and CKD grade 4 and higher dosages of magnesium oxide. Moreover, elevated serum Mg concentration was associated with magnesium oxide dosage exceeding 1000 mg/day, CKD grade 4, and the concurrent use of stimulant laxatives [32]. Milk alkali syndrome may also cause hypermagnesemia, as reported already in 1936 by Cope, where patients developed toxic symptoms of hypercalcemia, hyperphosphatemia, hypermagnesemia, and azotemia secondary to calcium carbonate-containing alkali therapy [33][34]. In patients undergoing dialysis, increased dialysate Mg can also cause symptomatic hypermagnesemia [35]. Moreover, a case report demonstrated hypermagnesemia in a patient with post-urethral irrigation with hemiacidrin, which is utilized in the nephrolithiasis process [36]. Moreover, excessive infusion of Mg sulfate during the management of eclampsia is a well-known cause of hypermagnesemia, which can be fatal [23][37]. Hypermagnesemia resulting solely from dietary intake is not reported thus far, as the kidneys effectively eliminate excess magnesium through urine. However, patients with CKD are more susceptible to developing hypermagnesemia due to impaired renal excretion. Hence, educating these patients about minimizing their consumption of magnesium-rich foods, such as seeds, nuts (such as almonds and cashews), black beans, brown rice, bananas, and broccoli, is crucial [38].

4.3. Mg Leak to the Extracellular Fluid

Mg is an essential intracellular cation. Consequently, in scenarios where hemolysis occurs due to various causes, including tumor lysis syndrome, there is a potential risk of developing hypermagnesemia [39]. Other causes which can present with hypermagnesemia through the extracellular shifts include rhabdomyolysis and metabolic acidosis, including diabetic ketoacidosis [40]. Metabolic acidosis causes urinary Mg wasting as a compensatory mechanism for the rapid rise in serum Mg [41]. Hence, chronic low-grade metabolic acidosis in humans eating Western diets may contribute to decreased Mg status [42].

References

  1. Al Alawi, A.M.; Majoni, S.W.; Falhammar, H. Magnesium and Human Health: Perspectives and Research Directions. Int. J. Endocrinol. 2018, 2018, 9041694.
  2. Gröber, U.; Schmidt, J.; Kisters, K. Magnesium in Prevention and Therapy. Nutrients 2015, 7, 8199–8226.
  3. Al Alawi, A.M.; Berhane, T.; Majoni, S.W.; Falhammar, H. Characteristics and health outcomes of patients hospitalised with hypomagnesaemia: A retrospective study from a single centre in the Northern Territory of Australia. Intern. Med. J. 2022, 52, 1544–1553.
  4. Cheungpasitporn, W.; Thongprayoon, C.; Qian, Q. Dysmagnesemia in Hospitalized Patients: Prevalence and Prognostic Importance. Mayo Clin. Proc. 2015, 90, 1001–1010.
  5. Workinger, J.L.; Doyle, R.P.; Bortz, J. Challenges in the Diagnosis of Magnesium Status. Nutrients 2018, 10, 1202.
  6. Huey, C.G.; Chan, K.M.; Wong, E.T.; Nelson, J.M.; Durand, M. Los Angeles County-University of Southern California Medical Center clinical pathology case conference: Extreme hypermagnesemia in a neonate. Clin. Chem. 1995, 41, 615–618.
  7. Oren, S.; Rapoport, J.; Zlotnik, M.; Brami, J.L.; Heimer, D.; Chaimovitz, C. Extreme hypermagnesemia due to ingestion of Dead Sea water. Nephron 1987, 47, 199–201.
  8. Syedmoradi, L.; Ghasemi, A.; Zahediasl, S.; Azizi, F. Prevalence of hypo- and hypermagnesemia in an Iranian urban population. Ann. Hum. Biol. 2011, 38, 150–155.
  9. Smith, J.M.; Lowe, R.F.; Fullerton, J.; Currie, S.M.; Harris, L.; Felker-Kantor, E. An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management. BMC Pregnancy Childbirth 2013, 13, 34.
  10. Altman, D.; Carroli, G.; Duley, L.; Farrell, B.; Moodley, J.; Neilson, J.; Smith, D. Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: A randomised placebo-controlled trial. Lancet 2002, 359, 1877–1890.
  11. Whang, R.; Ryder, K.W. Frequency of hypomagnesemia and hypermagnesemia. Requested vs routine. JAMA 1990, 263, 3063–3064.
  12. Felsenfeld, A.J.; Levine, B.S.; Rodriguez, M. Pathophysiology of Calcium, Phosphorus, and Magnesium Dysregulation in Chronic Kidney Disease. Semin. Dial. 2015, 28, 564–577.
  13. Cheungpasitporn, W.; Thongprayoon, C.; Bathini, T.; Hansrivijit, P.; Vaitla, P.; Medaura, J.; Vallabhajosyula, S.; Chewcharat, A.; Mao, M.A.; Erickson, S.B. Impact of admission serum magnesium levels on long-term mortality in hospitalized patients. Hosp. Pract. 2020, 48, 80–85.
  14. Haider, D.G.; Lindner, G.; Ahmad, S.S.; Sauter, T.; Wolzt, M.; Leichtle, A.B.; Fiedler, G.M.; Exadaktylos, A.K.; Fuhrmann, V. Hypermagnesemia is a strong independent risk factor for mortality in critically ill patients: Results from a cross-sectional study. Eur. J. Intern. Med. 2015, 26, 504–507.
  15. Tan, L.; Xu, Q.; Li, C.; Liu, J.; Shi, R. High-Normal Serum Magnesium and Hypermagnesemia Are Associated With Increased 30-Day In-Hospital Mortality: A Retrospective Cohort Study. Front. Cardiovasc. Med. 2021, 8, 625133.
  16. Li, J.; Imtiaz, M.S.; Beard, N.A.; Dulhunty, A.F.; Thorne, R.; vanHelden, D.F.; Laver, D.R. ß-Adrenergic stimulation increases RyR2 activity via intracellular Ca2+ and Mg2+ regulation. PLoS ONE 2013, 8, e58334.
  17. Fiaccadori, E.; Del Canale, S.; Coffrini, E.; Melej, R.; Vitali, P.; Guariglia, A.; Borghetti, A. Muscle and serum magnesium in pulmonary intensive care unit patients. Crit. Care Med. 1988, 16, 751–760.
  18. Sharma, R.; Heidari, A.; Johnson, R.H.; Advani, S.; Petersen, G. Serum magnesium levels in hospitalized patients with SARS-CoV-2. J. Investig. Med. 2022, 70, 409–414.
  19. Jahnen-Dechent, W.; Ketteler, M. Magnesium basics. Clin. Kidney J. 2012, 5, i3–i14.
  20. Bouillon-Minois, J.B.; Khaled, L.; Vitte, F.; Miraillet, L.; Eschalier, R.; Jabaudon, M.; Sapin, V.; Derault, L.; Kahouadji, S.; Brailova, M.; et al. Ionized Magnesium: Interpretation and Interest in Atrial Fibrillation. Nutrients 2023, 15, 236.
  21. Seo, J.W.; Park, T.J. Magnesium metabolism. Electrolyte Blood Press. 2008, 6, 86–95.
  22. Nishikawa, M.; Shimada, N.; Kanzaki, M.; Ikegami, T.; Fukuoka, T.; Fukushima, M.; Asano, K. The characteristics of patients with hypermagnesemia who underwent emergency hemodialysis. Acute Med. Surg. 2018, 5, 222–229.
  23. Cascella, M.; Vaqar, S. Hypermagnesemia; StatPearls Publishing: Treasure Island, FL, USA, 2023.
  24. Riccardi, D.; Brown, E.M. Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am. J. Physiol. Renal Physiol. 2010, 298, F485–F499.
  25. Iglesias, P.; Bajo, M.A.; Selgas, R.; Díez, J.J. Thyroid dysfunction and kidney disease: An update. Rev. Endocr. Metab. Disord. 2017, 18, 131–144.
  26. Woodward, A.; McCann, S.; Al-Jubouri, M. The relationship between estimated glomerular filtration rate and thyroid function: An observational study. Ann. Clin. Biochem. 2008, 45, 515–517.
  27. Brent, G.A. The molecular basis of thyroid hormone action. N. Engl. J. Med. 1994, 331, 847–853.
  28. Wu, Y.; Koenig, R.J. Gene regulation by thyroid hormone. Trends Endocrinol. Metab. 2000, 11, 207–211.
  29. Yen, P.M. Physiological and molecular basis of thyroid hormone action. Physiol. Rev. 2001, 81, 1097–1142.
  30. Yamaguchi, H.; Shimada, H.; Yoshita, K.; Tsubata, Y.; Ikarashi, K.; Morioka, T.; Saito, N.; Sakai, S.; Narita, I. Severe hypermagnesemia induced by magnesium oxide ingestion: A case series. CEN Case Rep. 2019, 8, 31–37.
  31. Shoaib Khan, M.; Zahid, S.; Ishaq, M. Fatal Hypermagnesemia: An acute ingestion of Epsom Salt in a patient with normal renal function. Caspian J. Intern. Med. 2018, 9, 413–415.
  32. Mori, H.; Suzuki, H.; Hirai, Y.; Okuzawa, A.; Kayashima, A.; Kubosawa, Y.; Kinoshita, S.; Fujimoto, A.; Nakazato, Y.; Nishizawa, T.; et al. Clinical features of hypermagnesemia in patients with functional constipation taking daily magnesium oxide. J. Clin. Biochem. Nutr. 2019, 65, 76–81.
  33. Cope, C.L. Base changes in the alkalosis produced by the treatment of gastric ulcer with alkalies. Clin. Sci. 1936, 2, 287–300.
  34. Medarov, B.I. Milk-alkali syndrome. Mayo Clin. Proc. 2009, 84, 261–267.
  35. Chakurkar, V.V.; Gade, P.S.; Godbole, A.V.; Wadia, F.F.; Lobo, V.A. Inadvertently high dialysate magnesium causing weakness and nausea in hemodialysis patients. Hemodial. Int. 2019, 23, E106–E110.
  36. Thompson, I.M.; Mora, R.V. Hypermagnesemia associated with hemiacidrin irrigation. J. Urol. 1984, 132, 741–742.
  37. Al Alawi, A.M.; Al Badi, A.; Al Huraizi, A.; Falhammar, H. Magnesium: The recent research and developments. Adv. Food Nutr. Res. 2021, 96, 193–218.
  38. Razzaque, M.S. Magnesium: Are We Consuming Enough? Nutrients 2018, 10, 1863.
  39. Wibe, E.; Kvaløy, S.; Nome, O.; Abrahamsen, A.F.; Bjørgo, S. Tumor lysis syndrome. A life-threatening complication during cytostatic treatment of chemosensitive types of cancer. Tidsskr. Nor. Laegeforen 1991, 111, 2435–2437.
  40. Swaminathan, R. Magnesium metabolism and its disorders. Clin. Biochem. Rev. 2003, 24, 47–66.
  41. Saris, N.E.; Mervaala, E.; Karppanen, H.; Khawaja, J.A.; Lewenstam, A. Magnesium. An update on physiological, clinical and analytical aspects. Clin. Chim. Acta. 2000, 294, 1–26.
  42. Caballero, B.; Allen, L.; Prentice, A. Encyclopedia of Human Nutrition; Elsevier Science: Amsterdam, The Netherlands, 2005.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Medical Laboratory Technology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Aya Hasan Aal-Hamad
,
Abdullah M. Al-Alawi
,
Masoud Salim Kashoub
,
Henrik Falhammar
View Times: 245
Revisions: 2 times (View History)
Update Date: 29 Jun 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Feedback